Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:

gamma-Butyrolactone: Target Organs and Levels of Evidence for TR-406

Toxicology and Carcinogenesis Studies of g-Butyrolactone (CASRN 96-48-0) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
Peer Review DateRoute/Exposure LevelsStudy Laboratory
MR: 0, 112, OR 225 MG/KG FR: 0, 225, OR 450 MG/KG M: 0, 262, OR 525 MG/KG; 50/SEX/SPECIES
Southern Research Institute

Levels of Evidence

Male Rats: No Evidence
Female Rats: No Evidence
TypeOrgan/Tissue (Lesion)
Other Considerations
  • MAMMARY GLAND: CYST 42/50 35/50 23/50; FIBROADENOMA 22/50 14/50 6/50
  • PITUITARY GLAND: CYST 25/49 13/37 11/48
Male Mice: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Adrenal Gland Medulla: PHEOCHROMOCYTOMA 1/48 5/50 1/50 OR MALIGNANT PHEOCHROMOCYTOMA 1/48 1/50 0/50 COMBINED 2/48 6/50 1/50
Non-Neoplastic Lesions
Other Considerations
  • LIVER: ADENOMA 8/50 6/50 1/50 OR CARCINOMA 16/50 2/50 8/50 COMBINED 24/50 8/50 9/50
Female Mice: No Evidence